Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Robert Charles Jahr currently holds 151,515 shares of Outlook Therapeutics, Inc. (OTLK), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Robert Charles Jahr has been a net neutral trader of OTLK stock. They have purchased $0 and sold $0 worth of shares.
Robert Charles Jahr's most recent insider trade was on Aug 14, 2026, when they purchased 151,515 shares at $0.00 per share.
Robert Charles Jahr serves as Executive at Outlook Therapeutics, Inc. (OTLK). They have executed 3 insider transactions totaling $0 over their tenure at the company.
Robert Charles Jahr holds the position of Executive at Outlook Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 1 years and currently hold a stake valued at $0.
Robert Charles Jahr has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Robert Charles Jahr was on Aug 14, 2026, when they purchased $0 worth of OTLK shares. This transaction involved 151,515 shares at N/A per share.
Robert Charles Jahr currently owns 151,515 shares of Outlook Therapeutics, Inc. (OTLK), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Robert Charles Jahr's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Robert Charles Jahr has 3 Form 4 filings on record as an insider at Outlook Therapeutics, Inc..
Set alerts for Robert Charles Jahr and 40,000+ other insiders.